146 related articles for article (PubMed ID: 15193547)
1. Bone turnover markers in patients with osteogenesis imperfecta.
Braga V; Gatti D; Rossini M; Colapietro F; Battaglia E; Viapiana O; Adami S
Bone; 2004 Jun; 34(6):1013-6. PubMed ID: 15193547
[TBL] [Abstract][Full Text] [Related]
2. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
Garnero P; Schott AM; Prockop D; Chevrel G
Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
[TBL] [Abstract][Full Text] [Related]
3. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations.
Rousseau JC; Chevrel G; Schott AM; Garnero P
Bone; 2010 Apr; 46(4):897-900. PubMed ID: 20005316
[TBL] [Abstract][Full Text] [Related]
4. In vitro expression of osteoblastic markers in cells isolated from normal fetal and postnatal human bone and from bone of patients with osteogenesis imperfecta.
Mörike M; Schulz M; Brenner RE; Bushart GB; Teller WM; Vetter U
J Cell Physiol; 1993 Dec; 157(3):439-44. PubMed ID: 8253854
[TBL] [Abstract][Full Text] [Related]
5. Intravenous neridronate in adults with osteogenesis imperfecta.
Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
[TBL] [Abstract][Full Text] [Related]
6. [Biochemical markers of bone turnover. New aspect. Metabolic bone markers in osteogenesis imperfecta].
Tanaka H
Clin Calcium; 2009 Aug; 19(8):1142-7. PubMed ID: 19638698
[TBL] [Abstract][Full Text] [Related]
7. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women.
Kaji T; Yasui T; Suto M; Mitani R; Morine M; Uemura H; Maeda K; Irahara M
Bone; 2007 Apr; 40(4):1088-94. PubMed ID: 17229597
[TBL] [Abstract][Full Text] [Related]
8. Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight.
Viapiana O; Gatti D; Dalle Grave R; Todesco T; Rossini M; Braga V; Idolazzi L; Fracassi E; Adami S
Bone; 2007 Apr; 40(4):1073-7. PubMed ID: 17240212
[TBL] [Abstract][Full Text] [Related]
9. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
10. Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women.
Gass ML; Kagan R; Kohles JD; Martens MG
Menopause; 2008; 15(4 Pt 1):667-75. PubMed ID: 18327152
[TBL] [Abstract][Full Text] [Related]
11. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations.
Roschger P; Fratzl-Zelman N; Misof BM; Glorieux FH; Klaushofer K; Rauch F
Calcif Tissue Int; 2008 Apr; 82(4):263-70. PubMed ID: 18311573
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers of bone turnover are influenced by recently sustained fracture.
Obrant KJ; Ivaska KK; Gerdhem P; Alatalo SL; Pettersson K; Väänänen HK
Bone; 2005 May; 36(5):786-92. PubMed ID: 15804493
[TBL] [Abstract][Full Text] [Related]
13. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.
Gur A; Colpan L; Cevik R; Nas K; Jale Sarac A
Clin Biochem; 2005 Jan; 38(1):66-72. PubMed ID: 15607319
[TBL] [Abstract][Full Text] [Related]
14. Total body bone mineral and tartrate-resistant acid phosphatase levels in type I and III osteogenesis imperfecta.
Rico H; Revilla M; Iritia M; Arribas I; Fernando Villa L
Miner Electrolyte Metab; 1991; 17(6):396-8. PubMed ID: 1823391
[TBL] [Abstract][Full Text] [Related]
15. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
Verit FF; Geyikli I; Yazgan P; Celik A
Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
[TBL] [Abstract][Full Text] [Related]
16. Telopeptides as markers of bone turnover in rheumatoid arthritis and osteoarthritis.
Wong PK; Young L; Vaile JH; Tan L; Bertouch JV; Bleasel JF; White C
Intern Med J; 2004; 34(9-10):539-44. PubMed ID: 15482266
[TBL] [Abstract][Full Text] [Related]
17. Serum markers of bone turnover in children and adolescents with classic galactosemia.
Gajewska J; Ambroszkiewicz J; Radomyska B; Chełchowska M; Ołtarzewski M; Laskowska-Klita T; Milanowski A
Adv Med Sci; 2008; 53(2):214-20. PubMed ID: 18650146
[TBL] [Abstract][Full Text] [Related]
18. Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta.
Kocijan R; Muschitz C; Fahrleitner-Pammer A; Amrein K; Pietschmann P; Haschka J; Dinu S; Kapiotis S; Resch H
J Clin Endocrinol Metab; 2014 Feb; 99(2):E311-9. PubMed ID: 24203063
[TBL] [Abstract][Full Text] [Related]
19. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
Colpan L; Gur A; Cevik R; Nas K; Sarac AJ
Maturitas; 2005 Jul; 51(3):246-53. PubMed ID: 15978968
[TBL] [Abstract][Full Text] [Related]
20. Osteogenesis imperfecta: clinical, cephalometric, and biochemical investigations of OI types I, III, and IV.
Jensen BL; Lund AM
J Craniofac Genet Dev Biol; 1997; 17(3):121-32. PubMed ID: 9338855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
